Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
REGULATORY
Zepbound, Qalsody, and More New Drugs Set for Japan Listing on March 19
Japan’s key reimbursement policy panel on March 12 gave the blessing to a batch of new medicines for listing later this month, including Eli Lilly’s obesity drug Zepbound (tirzepatide) and Biogen’s amyotrophic lateral sclerosis (ALS) treatment Qalsody (tofersen). A total…
To read the full story
Related Article
- Pfizer Rolls Out Hemophilia Therapy Hympavzi in Japan
March 25, 2025
- Datroway, Zeposia, and More Meds Now Available in Japan; Zepbound Launch Set for April 11
March 21, 2025
- JPA Asks for Price Penalty for High-Cost Meds with Packaging Unaligned to Dosing
March 14, 2025
- Biogen Japan to Launch ALS Drug Qalsody upon Listing on March 19
March 14, 2025
- Chuikyo Rep Calls for Proper Use of Zepbound, Frets Expansion of Obesity Market
March 13, 2025
- Imdelltra, Balversa, 2 More New Drugs Skip March Listing
March 13, 2025
- Japan Approves Zepbound, Qalsody, and Lots More Drugs
December 27, 2024
REGULATORY
- MHLW Panel Discusses Ways to Promote Clinical Trials
March 24, 2025
- PMDA Issues Guidance for Pediatric Drug Development
March 24, 2025
- US Chamber Raises Japan’s Pharma Policy as Unfair Trade Practice, Prods Federal Govt for Action
March 19, 2025
- MHLW to Investigate Pharmaceutical Ad Regulations in US, Europe
March 18, 2025
- MHLW Council OKs Public Knowledge Filing for Anaemetro’s Pediatric Use
March 17, 2025
The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…